Guillain-barré syndrome: A common neurological entity with myriad manifestations

Journal of Association of Physicians of India

Volumn 61, Issue 3, 2013, Pages 165-166

  Nadkar, Milind Y ^a   Bajpai, Smrati ^a   Itolikar, Manish ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR;

EDITORIAL; ELECTROMYOGRAPHY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOLOGY; MUSCLE WEAKNESS; NERVE CONDUCTION; PATHOLOGICAL REFLEX; PATHOPHYSIOLOGY; PLASMAPHERESIS; SKELETAL MUSCLE;

ELECTROMYOGRAPHY; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MUSCLE WEAKNESS; MUSCLE, SKELETAL; NEURAL CONDUCTION; PLASMAPHERESIS; REFLEX, ABNORMAL;

EID: 84875158459     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (22)

1. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology 2008;70:1608.
2. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 1994;17:1145.
3. Saifudheen K, Jose J, Gafoor VA, Musthafa M. Guillain-Barre syndrome and SIADH. Neurology 2011;76:701.
4. H o TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and antiglycolipid antibodies. Brain 1995;118 (Pt 3):597.
5. Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996;39:17.
6. Nagashima T, Koga M, Odaka M, et al. Clinical correlates of serum anti-GT1a IgG antibodies. J Neurol Sci 2004; 219:139.
7. Wicklein EM, Pfeiffer G, Yuki N, et al. Prominent sensory ataxia in Guillain-Barré syndrome associated with IgG anti-GD1b antibody. J Neurol Sci 1997;151:227.
8. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978; 3:565.
9. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366:2294.
10. H ahn AF. Guillain-Barré syndrome. Lancet 1998; 352:635.
11. R opper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1130.
12. Mori M, Kuwabara S, Miyake M, et al. Haemophilus influenzae infection and Guillain-Barré syndrome. Brain 2000;123 (Pt 10):2171.
13. Tam CC, O'Brien SJ, Rodrigues LC. Influenza, Campylobacter and Mycoplasma infections, and hospital admissions for Guillain-Barré syndrome, England. Emerg Infect Dis 2006; 12:1880.
14. Brannagan TH 3rd, Zhou Y. HIV-associated Guillain-Barré syndrome. J Neurol Sci 2003; 208:39.
15. Piliero PJ, Fish DG, Preston S, et al. Guillain-Barré syndrome associated with immune reconstitution. Clin Infect Dis 2003;36:e111.
16. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol 2002;51:673.
17. Jacobs BC, O'Hanlon GM, Bullens RW, et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003;126:2220.
18. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004;102:177.
19. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2012;78:1009.
20. H ughes RA. Ineffectiveness of high-dose intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1991;338:1142.
21. R ajabally YA, Uncini A. Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2012;83:711.
22. Dhadke SV, Dhadke VN, Bangar SS, Korade MB. Clinical Profile of Guillain Barre Syndrome. J Asso Physicians India 2013;61:168-172.